Page banner

#NHSChangeChallenge

Submitted
Thematic Analysis
Gathering votes
Filtration
Thanks for your vote
This voting milestone has now ended, and the idea has progressed to a private milestone
Thanks for approving the idea
This milestone has now ended, and the idea has progressed to a private milestone

Reviewing methods of drug delivery i.e. changing IV therpay to s/c where option available e.g. tocilizumab and potentially belimumab

by Bridget Griffiths | 7 months ago | in Rheumatology
Horizon 1

Decreasing footfall in the rheumatology day case unit so that we can ensure social distancing when our immunocompromised patients attend for treatment.

What is needed to sustain the change?

Ongoing access to these s/c drugs

What is your region?

North East

edited on Jul 13, 2020 by Kyle Beacham
Bridget Griffiths

Attach files

@

Sue Brown 7 months ago

I've heard positive comments from patients about this too - not having to come in for treatment is a benefit not just related to covid. Only negatives I have heard is where people are expected to self administer without having access to training on how to do it because no nurse was available to do the training.

Reply 0

Greta McLachlan 7 months ago

Status labels added: Choice, Community Care, Education, Medication, Patient Activation, Patient Selection, Staff & Patient Collaboration, Supported Self-Management, Horizon 1

Reply 0

Greta McLachlan 7 months ago

The idea has been progressed to the next milestone.

Reply 0

Kyle Beacham 6 months ago

Status labels removed: Choice, Community Care, Education, Medication, Patient Activation, Patient Selection, Staff & Patient Collaboration, Supported Self-Management

Reply 0

Share